NASDAQ · Biotechnology

SMMT (SMMT) Stock

$13.13 +0.84% NASDAQ: SMMT Healthcare

Valuation

MetricValue
Price$13.13
Market Cap$10.47B
P/E Ratio-16.20
P/B Ratio20.28
P/S Ratio0.00
EPS (TTM)$-1.44
52-Week High$30.98
52-Week Low$12.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-270.95%
ROA-1.48%
ROCE-224.18%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio9.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-64.0M$-60.0M$-478.0M$-181.0M$-1.1B
Net Profit$-66.0M$-65.0M$-482.0M$-177.0M$-1.1B
EPS$-0.71$-0.34$-0.78$-0.25$-1.44
Op Margin-4764.3%-10225.4%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$84.0M$541.0M$161.0M$348.0M$557.0M
Total Liabilities$22.0M$438.0M$99.0M$37.0M$69.0M
Cash$53.0M$284.0M$57.0M$84.0M$167.0M
Borrowings$2.0M$423.0M$84.0M$6.0M$16.0M

Latest News

Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT) InvestorsHub · Jul 22, 2026 Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Business Wire · Jul 22, 2026 Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study BioPharma Dive · Jul 22, 2026 Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 Business Wire · Jul 16, 2026 Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal Zacks · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-54.0M$-34.0M$-61.0M$-114.0M$-240.0M
Investing Cash Flow$0$-1.0M$-465.0M$-164.0M$-130.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$4.0M$470.0M$-457.0M$27.0M$89.0M
Free Cash Flow$-54.0M$-34.0M$-61.0M$-114.0M$-240.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-8.42
FCF Yield-2.59%
Quick Ratio7.41
Interest Coverage—
Return 1Y-44.46%
Return 3Y631.50%
Return 5Y84.49%

Ownership

Insiders Held83.14%
Institutions Held15.84%
Institutions Float Held93.92%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP36,391,0632026-03-31
FMR, LLC10,853,1992026-03-31
Blackrock Inc.9,653,7582026-03-31
Price (T.Rowe) Associates Inc8,277,8592026-03-31
State Street Corporation7,028,1602026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASNDAscendis Pharma A/S $243.45 -0.19% 25.59 $15.12B 0.00%
BBIOBridgeBio Pharma, Inc. $85.33 +1.56% -22.41 $16.71B 0.00%
EXASExact Sciences Corporation $104.91 — -95.37 $20.03B 0.00%
IONS $54.37 -2.84% -41.80 $8.99B 0.00%
MRNAModerna, Inc. $55.57 +2.76% -12.82 $22.05B 0.00%

About SMMT

SMMT is led by CEO Robert W. Duggan, employs 265 people, headquartered in Miami, US, publicly traded since 2015.

SMMT stock trades at $13.13 with a market capitalization of $10.47B. The stock is valued at a price-to-earnings (P/E) ratio of -16.20, price-to-book of 20.28, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.48 and $30.98, and currently trades 57.6% below its 52-week high.

On profitability, SMMT generates a return on equity (ROE) of -270.95%, return on capital employed of -224.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides